J.POD® 1 US provides uniquely flexible cGMP manufacturing of kilograms to metric tons of biologics therapeutics J.POD facility expands Just – Evotec Biologics’ capabilities into commercial…
J.POD® 2 EU biomanufacturing will play a key role in addressing the need for therapeutic antibodies, including those related to infectious diseases such as COVID-19
Just – Evotec Biologics’ Redmond, Washington site offers true meaning to “Facility of the Future” with flexible and podular manufacturing of clinical and commercial-stage biologics.…
Just – Evotec Biologics will manufacture anti-SARS-CoV-2 and other antibodies at its J.POD® manufacturing facility. Access to manufacturing capacity over a period of 7 years
Evotec gains access to Alloy Therapeutics’ ATX-Gx™ humanised mouse platform for biologics discovery Partnership leverages complementary strengths of in silico, in vitro and in vivo…
Just – Evotec Biologics receives grant for COVID-19 monoclonal antibody optimisation and cell line development from the COVID-19 therapeutics accelerator Grant enables the optimisation of…
Just – Evotec Biologics to provide process development and manufacturing of monoclonal antibody
Just – Evotec Biologics to provide process development required for phase I cGMP clinical manufacturing of broadly neutralising antibody against HIV
Partnership is part of a contract awarded to Ology Bioservices by the Department of Defense to develop and manufacture monoclonal antibodies for treatment and prevention…
Just – Evotec Biologics will apply its fully integrated technology platform in order to accelerate Oncoresponse’s lead product candidate through development and into the clinic
The J.POD® technology expands Evotec’s capabilities into flexible commercial biologics manufacturing Confirms Evotec’s role as leading external innovator for the integrated outsourcing of drug discovery…
• MSD to gain access to manufacturing know-how within Just – Evotec Biologics’ J.POD® facility (“Facility of the future”) • Multi-year collaboration in form of…